Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell symbols : Sana save search
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
Published: 2024-01-05 (Crawled : 14:00) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M
|
|
| O: 2.04%
H: 10.8%
C: 2.0%
sc262 fda drug clearance application
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
Published: 2023-12-11 (Crawled : 14:00) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M
|
|
| O: 0.0%
H: 1.88%
C: -2.15%
control tumor preclinical meeting
Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
Published: 2023-04-13 (Crawled : 15:00) - biospace.com/
SANA | $8.58 6.06% 5.71% 1.2M
|
|
| O: 1.87%
H: 29.97%
C: 28.27%
cd19 preclinical communications
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
Published: 2023-01-26 (Crawled : 23:00) - biospace.com/
SANA | $8.58 6.06% 5.71% 1.2M
|
|
| O: 1.49%
H: 1.05%
C: -3.15%
sc291 fda clearance drug application therapy
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
Published: 2022-12-11 (Crawled : 00:00) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M
|
|
| O: 0.24%
H: 9.42%
C: 6.76%
meeting six technology platform
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
Published: 2022-05-12 (Crawled : 22:00) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M
|
|
| O: 3.52%
H: 5.6%
C: 0.8%
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M
|
|
| O: 3.73%
H: 6.92%
C: 5.94%
america technology research cel preclinical cancer biotech iot t-cell pre-clinical
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M
|
| Email alert
Add to watchlist
technology presentation biotech iot platform t-cell
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.